Shivalik Rasayan Ltd Valuation Shifts to Very Attractive Amid Market Volatility

Valuation Metrics Highlight Renewed Appeal

At the core of Shivalik Rasayan’s improved valuation stance is its current price-to-earnings (P/E) ratio of 39.07, which, while elevated in absolute terms, is considerably lower than many of its peers in the pesticides and agrochemicals industry. For instance, Sanstar trades at a P/E of 63.22, Stallion India at 45.94, and Titan Biotech at a steep 67.14. This relative moderation in P/E suggests that Shivalik Rasayan’s shares are priced more reasonably given its earnings potential.

Complementing the P/E ratio, the price-to-book value (P/BV) stands at 0.77, indicating the stock is trading below its book value. This is a critical factor in the valuation upgrade, as it implies the market is valuing the company’s net assets conservatively, potentially offering a margin of safety for investors. The enterprise value to EBITDA (EV/EBITDA) multiple of 11.87 also supports this view, being significantly lower than peers such as Sanstar (54.09) and Titan Biotech (54.72), further underscoring the stock’s relative affordability.

Comparative Industry Context

When benchmarked against its industry peers, Shivalik Rasayan’s valuation metrics paint a picture of a micro-cap stock that is trading at a discount despite operating in a sector where many companies command premium multiples. For example, companies like I G Petrochems exhibit an extraordinary P/E of 588.15, reflecting either high growth expectations or speculative pricing. Meanwhile, other firms such as Gulshan Polyols and Oriental Aromatics, rated as 'attractive', trade at P/E multiples of 25.8 and 341.52 respectively, further highlighting Shivalik Rasayan’s comparatively modest valuation.

Its PEG ratio remains at 0.00, which may indicate either a lack of meaningful earnings growth projections or data unavailability, but this metric is less relevant given the company’s current valuation context. Dividend yield is minimal at 0.17%, reflecting limited income return for shareholders, which is typical for growth-oriented or turnaround micro-cap stocks.

Financial Performance and Returns

Despite the valuation appeal, Shivalik Rasayan’s recent financial performance and returns have been underwhelming. The company’s return on capital employed (ROCE) is 3.98%, and return on equity (ROE) is a modest 1.98%, both figures indicating limited profitability and capital efficiency. These metrics are likely contributors to the cautious market sentiment reflected in the Mojo Score of 45.0 and a 'Sell' grade, albeit an improvement from the previous 'Strong Sell' rating as of 25 May 2026.

Examining stock returns relative to the Sensex reveals a mixed picture. Over the past week and month, Shivalik Rasayan has outperformed the benchmark with gains of 13.26% and 10.10% respectively, while the Sensex declined by 0.85% and 3.51%. However, longer-term returns remain disappointing, with a one-year loss of 50.05% compared to an 8.40% gain in the Sensex, and a three-year decline of 61.75% against a 18.98% rise in the benchmark. Even over five and ten years, the stock has lagged significantly, though the ten-year return of 765.52% is notable, far exceeding the Sensex’s 180.55% gain, suggesting past periods of strong growth.

Market Capitalisation and Micro-Cap Status

Shivalik Rasayan remains classified as a micro-cap stock, which inherently carries higher volatility and risk compared to larger peers. Its market capitalisation grade reflects this status, and investors should weigh the potential for outsized returns against the elevated risk profile. The recent upgrade in valuation attractiveness may entice value-oriented investors seeking opportunities in underappreciated small caps within the pesticides and agrochemicals sector.

The stock’s recent price action, with a close at ₹292.20 on 1 June 2026, up from ₹257.75 the previous day, and a day’s trading range between ₹273.95 and ₹303.00, indicates heightened market activity. However, the 52-week high of ₹652.75 and low of ₹207.70 show a wide trading band, underscoring the stock’s volatility over the past year.

Peer Comparison and Relative Valuation

Among its peers, Shivalik Rasayan’s valuation stands out as 'very attractive' compared to others rated 'expensive' or 'very expensive'. For example, Stallion India and Titan Biotech, both rated 'very expensive', trade at P/E multiples above 45 and EV/EBITDA multiples exceeding 27 and 54 respectively. This contrast suggests that Shivalik Rasayan may offer a more compelling entry point for investors willing to accept the risks associated with its micro-cap status and modest profitability.

Conversely, companies like TGV Sraac, rated 'very attractive', trade at a much lower P/E of 9.09 and EV/EBITDA of 3.99, indicating that even within the attractive valuation category, there is a spectrum of pricing. Investors should consider these nuances when evaluating Shivalik Rasayan’s relative value proposition.

Outlook and Investor Considerations

While the valuation upgrade to 'very attractive' signals a positive shift in price attractiveness, investors must remain cautious given Shivalik Rasayan’s low profitability metrics and historical underperformance relative to the Sensex. The company’s modest ROCE and ROE suggest operational challenges that may limit near-term earnings growth, which is critical for sustaining higher valuations.

Moreover, the micro-cap classification implies liquidity constraints and higher susceptibility to market sentiment swings. The recent upgrade from a 'Strong Sell' to a 'Sell' grade by MarketsMOJO reflects some improvement in outlook but still advises prudence.

Investors should balance the potential for capital appreciation driven by valuation rerating against the risks posed by the company’s financial profile and sector dynamics. Comparing Shivalik Rasayan with other attractive or very attractive rated stocks in the pesticides and agrochemicals sector may help identify better risk-adjusted opportunities.

Summary

In summary, Shivalik Rasayan Ltd’s valuation parameters have improved markedly, with a P/E of 39.07 and P/BV of 0.77 positioning the stock as 'very attractive' relative to its peers. The recent price surge and upgrade in Mojo Grade from 'Strong Sell' to 'Sell' indicate a tentative market reassessment. However, subdued profitability and historical underperformance caution investors to conduct thorough due diligence and consider alternative options within the sector.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →